Skip to main content
Edward Barnes, MD, Gastroenterology, Chapel Hill, NC

Edward L Barnes MD MPH


Associate Professor of Medicine

Join to View Full Profile
  • 100 Eastowne DrChapel Hill, NC 27514

  • Phone+1 984-974-5050

  • Fax+1 919-843-6899

Dr. Barnes is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Education & Training

  • University of North Carolina Hospitals
    University of North Carolina HospitalsFellowship, Gastroenterology, 2016 - 2017
  • Mass General Brigham/Brigham and Women's Hospital
    Mass General Brigham/Brigham and Women's HospitalFellowship, Gastroenterology, 2013 - 2016
  • University of North Carolina Hospitals
    University of North Carolina HospitalsResidency, Internal Medicine, 2009 - 2012
  • University of South Carolina School of Medicine
    University of South Carolina School of MedicineClass of 2009

Certifications & Licensure

  • NC State Medical License
    NC State Medical License 2009 - 2027
  • TX State Medical License
    TX State Medical License 2024 - 2025
  • MA State Medical License
    MA State Medical License 2013 - 2016
  • Internal Medicine
    American Board of Internal Medicine Internal Medicine
  • Gastroenterology
    American Board of Internal Medicine Gastroenterology

Clinical Trials

Publications & Presentations

PubMed

Authored Content

  • Q&A: Updated AGA Guidance on Managing Post-IPAA PouchitisSeptember 2024

Press Mentions

  • Edward Barnes, MD, on Antibiotics and Risk of Pouchitis
    Edward Barnes, MD, on Antibiotics and Risk of PouchitisMay 6th, 2025
  • Weekly Roundup: 14 Health Press Releases You Need to See
    Weekly Roundup: 14 Health Press Releases You Need to SeeFebruary 14th, 2025
  • Most Patients on Lilly's Omvoh® (Mirikizumab-Mrkz) for Crohn's Disease Achieved Sustained Clinical Remission and Endoscopic Response at Two Years
    Most Patients on Lilly's Omvoh® (Mirikizumab-Mrkz) for Crohn's Disease Achieved Sustained Clinical Remission and Endoscopic Response at Two YearsFebruary 7th, 2025

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: